Trial Profile
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Double-Strand Break Repair Pathway Deficient Neoplasms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Niraparib (Primary)
- Indications Cholangiocarcinoma; Mesothelioma; Renal cell carcinoma; Solid tumours; Uveal melanoma
- Focus Therapeutic Use
- Acronyms UF-STO-ETI-001
- 04 Jan 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Primary endpoint has not been met (Objective Response Rate) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology